Log In Sign up
The largest database of trusted experimental protocols

Cobas taqman hiv 1 test version 2

Manufactured by Roche
Visit Supplier
Sourced in United States

The COBAS TaqMan HIV-1 Test Version 2.0 is a laboratory equipment product designed for the quantitative detection of HIV-1 RNA in human plasma and serum samples. It utilizes real-time PCR technology to measure the viral load in a patient's sample.

Automatically generated - may contain errors

Lab products found in correlation

Tritest cd4 cd8 cd3, by BD (1 mentions) Trucount, by BD (1 mentions) Facscalibur, by BD (1 mentions)

Close spelling variants of this product

Cobas TaqMan (73 citations) COBAS TaqMan HIV-1 Test (13 citations) TaqMan HIV-1 test (4 citations)

8 protocols using cobas taqman hiv 1 test version 2

1

HIV Viral Load Determination via COBAS TaqMan

Check if the same lab product or an alternative is used in the 5 most similar protocols
The HIV viral load was determined using a commercial nucleic acid amplification test (COBAS TaqMan HIV-1 Test Version 2.0, Roche Molecular Systems, Branchburg, NJ, USA), with a linear range between 34 and 10,000,000 copies of HIV RNA/mL.
Sultana C., Casian M., Oprea C., Ianache I., Grancea C., Chiriac D, & Ruta S. (2022). Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients. Medicina, 58(4), 531.
+ Open protocol
+ Expand
2

Measurement of HIV viral load and CD4+ cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV plasma viral load was determined with a commercial kit for nucleic acid amplification (COBAS TaqMan HIV-1 Test Version 2.0, Roche Molecular Systems, Branchburg, NJ, USA) with a linear range between 34 and 106 copies HIV RNA/mL.
CD4+ cell numbers were assessed by flow cytometry (BD Tritest CD4/CD8/CD3, Becton Dickinson, San Jose, CA, USA).
Rosca A., Anton G., Ene L., Iancu I., Temereanca A., Achim C.L, & Ruta S.M. (2016). Immunoassay and molecular methods to investigate DNA methylation changes in peripheral blood mononuclear cells in HIV infected patients on cART. Journal of immunoassay & immunochemistry, 38(3), 299-307.
+ Open protocol
+ Expand
3

Quantifying HIV Viral Load

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV viral load was determined with a commercial nucleic acid amplification test (COBAS TaqMan HIV-1 Test Version 2.0, Roche Molecular Systems, Branchburg, NJ), with a lower detection limit of 20 copies of HIV RNA/ml and a linear range between 34 and 10,000,000 copies HIV RNA/ml. Values ≤34 copies/ml were classified as undetectable for analysis.
Rosca A., Anton G., Botezatu A., Temereanca A., Ene L., Achim C, & Ruta S. (2016). miR-29a Associates With Viro-Immunological Markers of HIV Infection in Treatment Experienced Patients. Journal of medical virology, 88(12), 2132-2137.
+ Open protocol
+ Expand
4

Quantitative Analysis of CD4+ T Cells and Viral Load

Check if the same lab product or an alternative is used in the 5 most similar protocols
The CD4+ T cells were enumerated by a bead-based flow-cytometry kit (Trucount™, BD Biosciences Immunocytometry Systems, San Jose, CA, USA) and the plasma viral load was estimated with the Cobas Taqman HIV-1 test, version 2.0 (Roche, Branchburg, NJ, USA) according to manufacturer’s protocol.
Singh S., Toor J.S., Sharma A, & Arora S.K. (2020). Signature genes associated with immunological non-responsiveness to anti-retroviral therapy in HIV-1 subtype-c infection. PLoS ONE, 15(6), e0234270.
+ Open protocol
+ Expand
5

Retrospective HIV Cohort from Romania

Check if the same lab product or an alternative is used in the 5 most similar protocols
This analysis was a retrospective study on stored plasma samples collected from PWID admitted between 2010 and 2013 in a single tertiary facility (Victor Babes Hospital for Infectious Diseases). All patients had previously unknown HIV status, were hospitalized mainly for severe drug-related bacterial infections, and had provided informed consent. The study was approved by the Institutional Review Board of the Institute of Virology, Bucharest, Romania. Sixty-one patients were newly diagnosed with HIV infection (ELISA followed by Western Blot confirmation). Thirty-seven of these had both a viral load of >1000 copies/ml (determined with COBAS TaqMan HIV-1 Test Version 2.0, Roche Molecular Systems, Branchburg, NJ, USA; lower detection limit: 20 HIV RNA copies/mL) and a stored sample available for sequencing; all subjects were naïve to antiretroviral therapy.
Temereanca A., Oprea C., Wertheim J.O., Ianache I., Ceausu E., Cernescu C., Mehta S.R, & Ruta S. (2017). HIV transmission clusters among injecting drug users in Romania. Romanian biotechnological letters, 22(1), 12307-12315.
+ Open protocol
+ Expand
6

Immunological Profiling in HIV-Toxoplasma Coinfection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples were collected at the time of NC assessment. Lymphocyte subsets were measured immediately while other laboratory analyses were performed from samples stored at −80°C. T (CD4+ and CD8+), B and NK-lymphocyte subsets in the peripheral blood were measured by flow cytometry (4 colours MultiTest and FACSCalibur, Becton Dickinson). HIV-1 viral load was assessed using a commercial nucleic acid amplification test (COBAS TaqMan HIV-1 Test Version 2.0, Roche Molecular Systems, Branchburg, USA), with a lower detection limit of 20 copies of HIV RNA/mL and a linear range between 34 - 10000000 copies HIV RNA/mL.
Toxoplasma IgG and IgM levels were measured by a quantitative enzyme immunoassay (DiaPro, Italy). Toxoplasma IgG antibody level was dichotomised as high or low based on the median value of Toxoplasma positive levels of the entire study (1088 UI/ml).
Ene L., Marcotte T., Umlauf A., Grancea C., Temereanca A., Bharti A., Achim C., Letendre S, & Ruta S. (2016). Latent toxoplasmosis is associated with neurocognitive impairment in young adults with and without chronic HIV infection. Journal of neuroimmunology, 299, 1-7.
+ Open protocol
+ Expand
7

Dolutegravir-Lamivudine Therapy for HIV-Infected Inpatients

Check if the same lab product or an alternative is used in the 5 most similar protocols
This is a single-center, retrospective-prospective, observational study, and we included all treatment-naive HIVinfected inpatients who started ART using DTG + 3TC regimen from January 2019 to September 2020 for various clinical reasons in the Third People's Hospital of Shenzhen, China. The study was approved by the Third People's Hospital of Shenzhen Ethics Committee (No. 2020-050). Written informed consent was obtained from all participants. Baseline and each follow-up visit data of the all patients were collected, including demographic and clinical characteristics and laboratory results. HIV-1 plasma RNA was measured with Roche COBAS TaqMan HIV-1 test version 2.0, threshold of which is 20 copies/mL.
Zhao F., Rao M., Chen W., Cai K., Zhang L., Xu L., Sun L., Liu X., He Y, & Wang H. (2022). Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World. Journal of acquired immune deficiency syndromes (1999), 91(S1).
+ Open protocol
+ Expand
8

Quantitative Viral Load Monitoring in ART

Cited 3 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma VL was measured quantitatively with the Roche Amplicor version 1.5 ultrasensitive assay with a lower limit of quantification of 50 copies/mL (Roche Diagnostics), before replacement with the COBAS TaqMan HIV-1 Test version 2.0 (Roche Diagnostics) with a lower limit of quantification of 20 copies/mL. Plasma VL was measured at the time of study enrollment, every 2 weeks from the date of enrollment through week 4 of ART, every 4 weeks from week 4 through week 24 of ART, and every 12 weeks thereafter. Single-copy HIV-1 RNA levels were measured retrospectively using ultrasensitive hybrid real-time/digital PCR, as previously described (51 (link), 52 (link)). The AUC was calculated by adding the AUC measured in the study starting at ART initiation and the estimated AUC at each AHI stage derived from the VL trendline in untreated AHI (23 (link), 30 (link)).
Mitchell J.L., Pollara J., Dietze K., Edwards R.W., Nohara J., N’guessan K.F., Zemil M., Buranapraditkun S., Takata H., Li Y., Muir R., Kroon E., Pinyakorn S., Jha S., Manasnayakorn S., Chottanapund S., Thantiworasit P., Prueksakaew P., Ratnaratorn N., Nuntapinit B., Fox L., Tovanabutra S., Paquin-Proulx D., Wieczorek L., Polonis V.R., Maldarelli F., Haddad E.K., Phanuphak P., Sacdalan C.P., Rolland M., Phanuphak N., Ananworanich J., Vasan S., Ferrari G, & Trautmann L. (2022). Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. The Journal of Clinical Investigation, 132(1), e150937.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!